Whether alcohol, cocaine, nicotine, and cannabis damage the same brain regions or different brain regions has been hard to settle in the addiction-imaging literature. A 2026 ENIGMA Addiction analysis by Georgiadis et al. — pooling 4,733 brains across 51 sites — now has an answer. Research Highlights Across 2,782 people with substance use disorder (SUD) …
A 2026 meta-analysis of 56 controlled trials found the clearest gamma-frequency neuromodulation signal in schizophrenia: overall symptoms improved vs. control (g = −0.46), global cognition improved (g = 0.55), and MDD showed a smaller depression effect than the schizophrenia symptom estimate (g = −0.34). Bipolar disorder and autism stayed directional but nonsignificant, and the paper’s …
A 2026 hospital MRI study found that the left paracingulate sulcus was present in 31 of 109 catatonia patients (28%) vs. 171 of 323 psychiatric controls without catatonia (53%), a left-hemisphere group effect that survived adjustment for age, sex, scanner, brain volume, benzodiazepines, and antipsychotics.1 Research Highlights Left PCS signal: left paracingulate sulcus (PCS) presence …
First-generation antipsychotic (FGA) shortages are not just pharmacy annoyances; they force medication changes in people who may have taken years to stabilize on a tolerable regimen. Research Highlights 95,968 patients: Tabah 2026 used Komodo claims data to study people with psychotic-spectrum diagnoses taking shortage-affected first-generation antipsychotics. Switching was not evenly distributed: molindone reached 100% switching, …
Patients with schizophrenia have substantially elevated dementia risk compared to the general population — roughly 2-3 times the age-adjusted rate — but the specific drivers within the schizophrenia population have been less well characterized. A 2026 case-control study by Ho et al. used population-based data to identify which factors specifically elevate dementia risk among schizophrenia …
Clozapine is the only medication with proven efficacy for treatment-resistant schizophrenia, yet most eligible patients wait years before starting it. A 2026 paper by Perfalk and colleagues trains a machine-learning model on routine electronic health record data to flag candidates earlier.1 Research Highlights Clozapine is the only evidence-based treatment for treatment-resistant schizophrenia (TRS), but the …
Lurasidone is approved for schizophrenia and bipolar depression on the strength of acute trials that mostly reported a single number: the change in PANSS total score. A 2026 post-hoc analysis of the JEWEL Phase 3 trial pulls that number apart, looking separately at five symptom domains and at all 30 individual items of the PANSS …